SSB and Bosch Announce Global Collaboration
News Jun 21, 2012
Sartorius Stedim Biotech (SSB) and Bosch Packaging Technology (Bosch) have announced a long-term global partnership agreement. The agreement covers the mutual design and development of single-use filling solutions to be used on Bosch’s aseptic filling equipment for final fill-and-finish operations of drug products.
SSB will provide Bosch with pre-configured single-use filling transfer sets, consisting of bags, filters, tubing and connectors.
Bosch will combine them with its aseptic filling and barrier isolation technology into new, innovative systems for aseptic filling, and exclusively market, distribute and service these new filling systems under its own brand name.
With the new product line PreVAS (Pre-Validated, Pre-Assembled, Pre-Sterilized), Bosch will supply its customers with highly cost effective, plug and play tools for aseptic filling operations that provide additional flexibility and come along with comprehensive validation packages. PreVAS will be launched at Achema 2012.
Joachim Brenner, responsible for Bosch’s Pharma Liquid portfolio worldwide and Site Manager of the plant Crailsheim, stated: “By integrating SSB’s single-use technologies into our aseptic filling systems, we are expanding our product and service portfolio in the area of fill-and-finish unit operations by an important component. With our joint expertise, we intend to develop configurable and customized single-use filling solutions and to provide strong validation and technical support.”
Jean-Marc Cappia, Vice President of Marketing, Fluid Management Technologies, at SSB stated: “The partnership with Bosch promotes the implementation of single-use technologies into critical applications such as final filling operations and strengthens the confidence into single-use technology. Our customers from the pharmaceutical and biopharmaceutical industry are facing mounting cost pressure and time constraints. By integrating single-use technology into fill-and-finish unit operations, they can handle smaller batches and product change overs in a safe, economic and flexible way.”
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE